JP7823036B2 - アセトアミド－フェニルテトラゾール誘導体およびその使用方法 - Google Patents

アセトアミド－フェニルテトラゾール誘導体およびその使用方法

Info

Publication number
JP7823036B2
JP7823036B2 JP2023521299A JP2023521299A JP7823036B2 JP 7823036 B2 JP7823036 B2 JP 7823036B2 JP 2023521299 A JP2023521299 A JP 2023521299A JP 2023521299 A JP2023521299 A JP 2023521299A JP 7823036 B2 JP7823036 B2 JP 7823036B2
Authority
JP
Japan
Prior art keywords
heteroatoms selected
membered
substituted
alkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023521299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544615A (ja
JP2023544615A5 (enExample
Inventor
サミール ウルガオンカー
アハメド エム． セッド
アブデル サイード ネーダー エヌ． ナシーフ
ローラ ベス ピツゾンカ
マリー ジョン カトラー
マイケル ピー． スモリンスキ
ジョンソン イウ－ナム ラウ
Original Assignee
ヘルス ホープ ファーマ エイチケー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘルス ホープ ファーマ エイチケー リミテッド filed Critical ヘルス ホープ ファーマ エイチケー リミテッド
Publication of JP2023544615A publication Critical patent/JP2023544615A/ja
Publication of JP2023544615A5 publication Critical patent/JP2023544615A5/ja
Priority to JP2026024155A priority Critical patent/JP2026090442A/ja
Application granted granted Critical
Publication of JP7823036B2 publication Critical patent/JP7823036B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023521299A 2020-10-07 2021-10-07 アセトアミド－フェニルテトラゾール誘導体およびその使用方法 Active JP7823036B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026024155A JP2026090442A (ja) 2020-10-07 2026-02-18 アセトアミド－フェニルテトラゾール誘導体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063088788P 2020-10-07 2020-10-07
US63/088,788 2020-10-07
PCT/US2021/053937 WO2022076663A1 (en) 2020-10-07 2021-10-07 Acetamido-phenyltetrazole derivatives and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026024155A Division JP2026090442A (ja) 2020-10-07 2026-02-18 アセトアミド－フェニルテトラゾール誘導体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2023544615A JP2023544615A (ja) 2023-10-24
JP2023544615A5 JP2023544615A5 (enExample) 2024-10-04
JP7823036B2 true JP7823036B2 (ja) 2026-03-03

Family

ID=78483546

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023521299A Active JP7823036B2 (ja) 2020-10-07 2021-10-07 アセトアミド－フェニルテトラゾール誘導体およびその使用方法
JP2026024155A Pending JP2026090442A (ja) 2020-10-07 2026-02-18 アセトアミド－フェニルテトラゾール誘導体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026024155A Pending JP2026090442A (ja) 2020-10-07 2026-02-18 アセトアミド－フェニルテトラゾール誘導体およびその使用方法

Country Status (11)

Country Link
US (1) US11739089B2 (enExample)
EP (1) EP4225747A1 (enExample)
JP (2) JP7823036B2 (enExample)
KR (1) KR20230104151A (enExample)
CN (1) CN116964044B (enExample)
AU (1) AU2021358074A1 (enExample)
CA (1) CA3194694A1 (enExample)
IL (1) IL301516A (enExample)
MX (1) MX2023003933A (enExample)
TW (1) TWI900672B (enExample)
WO (1) WO2022076663A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN110312130B (zh) * 2019-06-25 2021-10-15 浙江大华技术股份有限公司 基于三角模式的帧间预测、视频编码方法及设备
WO2022076663A1 (en) 2020-10-07 2022-04-14 Athenex, Inc. Acetamido-phenyltetrazole derivatives and methods of using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517267A (ja) 2010-01-15 2013-05-16 ハンミ・サイエンス・カンパニー・リミテッド テトラゾールメタンスルホン酸塩の製造方法及びそれに用いられる新規化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5663179A (en) 1992-07-10 1997-09-02 Laboratoires Glaxo Sa Certain isoquinoline derivatives having anti-tumor properties
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
GB9717576D0 (en) 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
KR100557093B1 (ko) 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
WO2015152433A1 (en) 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
TWI715636B (zh) 2015-09-30 2021-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
TWI833710B (zh) 2017-10-06 2024-03-01 香港商慧源香港創新有限公司 高單位含量口服型紫杉烷組合物及方法
WO2022076663A1 (en) 2020-10-07 2022-04-14 Athenex, Inc. Acetamido-phenyltetrazole derivatives and methods of using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517267A (ja) 2010-01-15 2013-05-16 ハンミ・サイエンス・カンパニー・リミテッド テトラゾールメタンスルホン酸塩の製造方法及びそれに用いられる新規化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chemistry，2014年05月07日，Vol.25, No.6，p.1137-1142
In Silico Pharmacology，2021年01月03日，Vol.9(1):6，p.1-7，https://doi.org/10.1007//s40203-020-00066-7
RAPID COMMUNICATIONS IN MASS SPECTROMETRY，2006年03月04日，Vol.20，p.1457-1462

Also Published As

Publication number Publication date
JP2023544615A (ja) 2023-10-24
CN116964044B (zh) 2026-03-06
KR20230104151A (ko) 2023-07-07
US11739089B2 (en) 2023-08-29
AU2021358074A1 (en) 2023-04-27
MX2023003933A (es) 2023-07-05
CN116964044A (zh) 2023-10-27
IL301516A (en) 2023-05-01
CA3194694A1 (en) 2022-04-14
US20220106312A1 (en) 2022-04-07
TWI900672B (zh) 2025-10-11
TW202233593A (zh) 2022-09-01
EP4225747A1 (en) 2023-08-16
JP2026090442A (ja) 2026-06-02
WO2022076663A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
TWI896726B (zh) 一種ｅｇｆｒ抑制劑及其製備方法和應用
EP3555070B1 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
CN113316576A (zh) 用于治疗癌症的作为HPK1抑制剂的2,3-二氢-1H-吡咯并[3,4-c]吡啶-1-酮衍生物
CN107922418A (zh) 抗微生物化合物及制备和使用所述化合物的方法
JP7106659B2 (ja) インドール－２、３－ジオキシゲナーゼ阻害剤としてのスピロ化合物
TWI900672B (zh) 乙醯胺基－苯基四唑衍生物及其使用方法
JP2019532950A (ja) Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
WO2024026419A1 (en) Quinoxaline derivatives as pik3 alpha modulators
WO2024026424A1 (en) Quinazolinone derivatives as and related uses
JP2026515712A (ja) 半飽和二環式誘導体および関連する使用
WO2024026423A1 (en) Substituted quinoline derivatives as pi3k inhibitors
JP7823035B2 (ja) アセトアミド－フェニルベンズアミド誘導体およびその使用方法
WO2022266425A1 (en) 3-cyano-quinoline derivatives and uses thereof
CN120265635A (zh) 抗癌核激素受体靶向化合物
CN118176181A (zh) Sarm1调节剂、其制备和用途
HK40102895A (en) Acetamido-phenylbenzamide derivatives and methods of using the same
HK40112482A (en) Sarm1 modulators, preparations, and uses thereof
WO2024067463A1 (zh) 苯并[7]环烯类衍生物、包含其的药物组合物及其医药用途
AU687414B2 (en) Piperidinyl substituted methanoanthracenes as D1/D2-antagonists and 5HT2-serotanin-antagonists
CN121045184A (zh) Wrn抑制剂及其用途
CN107235960A (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
HK40053093A (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250714

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260218

R150 Certificate of patent or registration of utility model

Ref document number: 7823036

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150